Titan Pharmaceuticalsincis A Biopharmaceutical Company Located In South San Franciscocaliforniafounded In 1992It Is Publicly Traded On The Nasdaq Under The Ticker Symbol Ttnpthe Company Specializes In Developing Proprietary Therapeutics For Chronic Diseasesleveraging Its Unique Long Term Drug Delivery Platform Known As Proneura The Proneura Technology Features A Smallsolid Implant That Allows For Subdermal Drug Administrationproviding Steady State Deliverytitan S Key Productprobuphineis A Buprenorphine Implant Approved For The Maintenance Treatment Of Opioid Use Disorder In Stable Patientsalthough Titan Discontinued Its Commercialization In The U Sin 2020It Is Still Marketed In The Eu Under The Name Sixmothe Company Is Also Developing Other Productsincluding A Nalmefene Implant And A Kappa Opioid Receptor Agonist For Chronic Pruritus Titan Has Established Partnershipsincluding Licensing Its European Rights For Probuphine To Moltenian Italian Pharmaceutical Companyin 2024Titan Entered Into A Merger Agreement And Became A Wholly Owned Subsidiary Of Bske Ltddavid Lazar Currently Serves As The Chairman And Ceo
No conferences found for this company.
| Company Name | Titan Pharmaceuticals Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
